Neurocrine Biosciences, Inc. (NBIX) Income Statement
NBIX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNBIX revenue and net income
Where NBIX's revenue goes
2025Each bar shows an amount and its share of revenue. NBIX kept 16.7% of revenue as net income.
NBIX profit margins
NBIX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +21.4% | +24.3% | +22.3% | +64.5% |
| Gross profit | +21.0% | +24.2% | +22.1% | +64.2% |
| Operating income | +8.5% | +35.5% | +30.6% | — |
| Net income | +40.2% | +45.8% | +3.3% | — |
| EPS (diluted) | +1.1% | +22.8% | +9.2% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NBIX quarterly EPS vs estimates
Neurocrine Biosciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 2, 2026 (estimate $1.98).
NBIX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.1M | $451.2M | $161.6M | $15.0M |
| Cost of revenue | $52.1M | $34.0M | $39.7M | $23.2M | $14.3M | $10.1M | $7.4M | $4.9M | $1.3M | $35.9M |
| Gross profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | $780.7M | $446.4M | $160.4M | $15.0M |
| Research & development | $1.02B | $731.1M | $565.0M | $463.8M | $328.1M | $275.0M | $200.0M | $160.5M | $91.8M | $94.3M |
| Sales, general & admin | $1.16B | $1.01B | $851.6M | $752.7M | $583.3M | $433.3M | $354.1M | $248.9M | $169.9M | $68.1M |
| Total operating expenses | $2.19B | $1.75B | $1.60B | $1.22B | $1.02B | $872.8M | $708.4M | $409.5M | $291.7M | $162.4M |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M | $72.3M | $36.9M | −$131.4M | −$147.4M |
| Interest income | $90.3M | $91.0M | $52.8M | $4.1M | — | — | $25.7M | $15.1M | $13.3M | $2.8M |
| Interest expense | — | $126.6M | $4.6M | $7.1M | $25.8M | $32.8M | $32.0M | $30.5M | $19.5M | $0 |
| Income before taxes | $705.4M | $486.0M | $332.1M | $213.9M | $101.4M | $106.7M | $46.5M | $21.8M | −$142.5M | −$141.1M |
| Income taxes | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M | −$300.6M | $9.5M | $730,000 | $17.1M | −$7.7M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M | −$142.5M | −$141.1M |
| EBITDA | $666.6M | $639.7M | $416.1M | $264.6M | $138.1M | $148.1M | $85.9M | $40.9M | −$120.6M | −$139.6M |
| EPS (diluted) | $6.40 | $6.33 | $3.82 | $3.46 | $1.80 | $4.12 | $0.33 | $0.17 | −$1.64 | −$1.62 |
| Gross margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | 99.1% | 98.9% | 99.2% | 100.0% |
| Operating margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | −81.3% | −982.5% |
| Net margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | −88.2% | −940.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959.0M | $814.5M | $805.5M | $794.9M | $687.5M | $572.6M | $627.7M | $622.1M | $590.2M | $515.3M | $515.2M | $498.8M |
| Cost of revenue | $23.2M | $13.8M | $17.6M | $14.0M | $11.3M | $9.2M | $9.3M | $8.0M | $9.2M | $7.5M | $8.5M | $11.2M |
| Gross profit | $935.8M | $800.7M | $787.9M | $780.9M | $676.2M | $563.4M | $618.4M | $614.1M | $581.0M | $507.8M | $506.7M | $487.6M |
| Research & development | $326.7M | $296.2M | $258.2M | $250.0M | $244.3M | $263.2M | $185.6M | $195.0M | $191.1M | $159.4M | $137.5M | $142.2M |
| Sales, general & admin | $439.7M | $318.5M | $301.8M | $291.6M | $286.3M | $276.5M | $287.8M | $234.3M | $242.0M | $243.1M | $218.9M | $204.2M |
| Total operating expenses | $782.8M | $614.7M | $577.0M | $541.9M | $530.6M | $539.8M | $476.4M | $430.3M | $435.6M | $408.5M | $356.4M | $346.4M |
| Operating income | $153.0M | $186.0M | $210.9M | $239.0M | $145.6M | $23.6M | $142.0M | $183.8M | $145.4M | $99.3M | $150.3M | $141.2M |
| Interest expense | $2.9M | — | — | — | $0 | — | — | — | $49.7M | $1.1M | $1.1M | $1.1M |
| Income before taxes | $162.2M | $246.8M | $239.4M | $291.8M | $159.5M | $14.7M | $162.6M | $190.3M | $98.6M | $34.5M | $198.2M | $115.6M |
| Income taxes | $17.8M | $48.9M | $85.7M | $82.3M | $52.0M | $6.8M | $59.5M | $60.5M | $33.6M | −$8.9M | $50.5M | $32.5M |
| Net income | $144.4M | $197.9M | $153.7M | $209.5M | $107.5M | $7.9M | $103.1M | $129.8M | $65.0M | $43.4M | $147.7M | $83.1M |
| EBITDA | $189.9M | $193.3M | $235.4M | $299.5M | $166.8M | $31.3M | $181.7M | $191.3M | $155.2M | $111.5M | $205.0M | $122.2M |
| EPS (diluted) | $2.36 | $1.94 | $1.88 | $2.17 | $1.65 | $0.70 | $1.69 | $1.81 | $1.63 | $1.20 | $1.54 | $1.54 |
| Gross margin | 97.6% | 98.3% | 97.8% | 98.2% | 98.4% | 98.4% | 98.5% | 98.7% | 98.4% | 98.5% | 98.4% | 97.8% |
| Operating margin | 16.0% | 22.8% | 26.2% | 30.1% | 21.2% | 4.1% | 22.6% | 29.5% | 24.6% | 19.3% | 29.2% | 28.3% |
| Net margin | 15.1% | 24.3% | 19.1% | 26.4% | 15.6% | 1.4% | 16.4% | 20.9% | 11.0% | 8.4% | 28.7% | 16.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NBIX's financial statements (latest annual report filed February 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NBIX financial results
In fiscal year 2025 (ended December 31, 2025), Neurocrine Biosciences reported revenue of $2.9 billion, up 21.4% from the year before. It had net income of $478.6 million (up 40.2%), a net profit margin of 16.7%. Diluted earnings per share came to $6.40. Over five years revenue grew at an average rate of 22.3% a year.
See the NBIX stock overview for the latest quote and news, or the NBIX chart for price history and technical indicators.
NBIX income statement FAQ
What is Neurocrine Biosciences's annual revenue?
Neurocrine Biosciences reported total revenue of $2.9 billion for fiscal year 2025, which ended on December 31, 2025. That was up 21.4% from $2.4 billion the previous year.
Is Neurocrine Biosciences profitable?
Yes. Neurocrine Biosciences reported net income of $478.6 million in fiscal 2025, a net profit margin of 16.7%; its operating margin was 21.6%.
What is Neurocrine Biosciences's gross margin?
Neurocrine Biosciences's gross margin was 98.2% in fiscal 2025: for every $100 of revenue, Neurocrine Biosciences kept $98 after the direct cost of its products and services.
How much does Neurocrine Biosciences spend on research and development?
Neurocrine Biosciences spent $1.0 billion on research and development in fiscal 2025, 35.5% of revenue.
How fast is Neurocrine Biosciences growing?
Revenue grew 22.3% a year on average over the last five fiscal years, from $1.0 billion to $2.9 billion.
What are Neurocrine Biosciences's earnings per share?
Neurocrine Biosciences earned $6.40 per diluted share in fiscal 2025, compared with $6.33 a year earlier.
When will Neurocrine Biosciences report its next earnings?
Neurocrine Biosciences is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes.
When does Neurocrine Biosciences's fiscal year end?
Neurocrine Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 11, 2026.